Advertisement

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer
Posted: 05/18/2022 | By: Sarah Campen, PharmD

Question 1 of 5

Which of the following statements is FALSE regarding orteronel?

Choose 1

A
Orteronel is a novel CYP17 inhibitor
B
The recommended dose of orteronel is 300 mg twice daily
C
Orteronel must be co-administered with corticosteroids because of inhibition of CYP17 hydroxylase
D
Hypertension is a commonly occurring side effect of orteronel treatment

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage